Last reviewed · How we verify
Nabilone Capsules
Nabilone is a synthetic cannabinoid that mimics THC and activates cannabinoid receptors in the central nervous system to reduce nausea and vomiting.
Nabilone is a synthetic cannabinoid that mimics THC and activates cannabinoid receptors in the central nervous system to reduce nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Post-operative nausea and vomiting.
At a glance
| Generic name | Nabilone Capsules |
|---|---|
| Sponsor | Eldon Loh, MD |
| Drug class | Synthetic cannabinoid |
| Target | CB1 receptor, CB2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Nabilone acts as a partial agonist at CB1 and CB2 cannabinoid receptors, primarily in the chemoreceptor trigger zone and vomiting center of the brain. This mechanism suppresses the signals that trigger nausea and emesis, making it effective for chemotherapy-induced nausea and vomiting (CINV) and other conditions associated with severe nausea.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Post-operative nausea and vomiting
Common side effects
- Dizziness
- Drowsiness
- Euphoria
- Dry mouth
- Ataxia
- Headache
Key clinical trials
- Investigating the Effects of Nabilone on Endocannabinoid Metabolism (PHASE4)
- Nabilone for Agitation Blinded Intervention Trial (PHASE3)
- Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities (PHASE1)
- Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury (PHASE3)
- Nabilone for Agitation in Frontotemporal Dementia (PHASE2)
- Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder (PHASE1, PHASE2)
- A Pilot Trial of Nabilone for the Treatment of Obesity (PHASE2)
- DIalysis Symptom COntrol-Pruritus Outcome Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nabilone Capsules CI brief — competitive landscape report
- Nabilone Capsules updates RSS · CI watch RSS
- Eldon Loh, MD portfolio CI